Hanspeter Spek - Genpact Independent Director
| G Stock | USD 31.65 0.11 0.35% |
Director
Mr. Hanspeter Spek is an Independent Director of Genpact Limited. In 2013, he retired as president, global operations of Sanofi S.A., where he had served in leadership roles since 1985, including as executive vice president of global pharmaceutical operations. Prior to joining Sanofi Pharma in 1985, he held various positions at Pfizer International, Inc. in Germany. Mr. Spek also sits on the board of directors of Celyad S.A., formerly Cardio3 BioSciences SA, and previously served on the board of directors of Celesio AG until 2014. The board concluded that Mr. Spek is well suited to serve as a director because of his international experience and his extensive expertise in the pharmaceuticals industry. since 2014.
| Age | 66 |
| Tenure | 10 years |
| Address | Canon's, Court, Hamilton, Bermuda, HM 12 |
| Phone | 441 298 3300 |
| Web | https://www.genpact.com |
Genpact Management Efficiency
The company has return on total asset of 0.083 % which means that for every 100 dollars spent on assets, it generated a profit of $0.083. This is way below average. Similarly, it shows a return on equity (ROE) of 0.3099 %, implying that it made 0.3099 on every $100 invested by shareholders. Genpact's management efficiency ratios could be used to measure how well Genpact manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Genpact's Return On Equity is most likely to increase slightly in the upcoming years. At this time, Genpact's Intangibles To Total Assets are most likely to slightly decrease in the upcoming years. The Genpact's current Return On Assets is estimated to increase to 0.14, while Other Assets are projected to decrease to 0.95.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| John Harris | The Hackett Group | 70 | |
| Richard Hamlin | The Hackett Group | 70 | |
| Amir Nechmad | Nayax | 65 | |
| Robert Rivero | The Hackett Group | 76 | |
| Alan Wix | The Hackett Group | 76 | |
| Iris Yahal | Formula Systems 1985 | 53 | |
| Eliyahu Zamir | Formula Systems 1985 | 46 | |
| Marilyn Smith | CSP Inc | 68 | |
| Edwin Huston | The Hackett Group | 75 | |
| Ismail Azeri | CSP Inc | 38 | |
| Eliahu Zamir | Formula Systems 1985 | 47 | |
| Rafal Kozlowski | Formula Systems 1985 | 41 | |
| Marek Panek | Formula Systems 1985 | 45 | |
| Dafna Cohen | Formula Systems 1985 | 45 | |
| Raymond Blackmon | CSP Inc | 68 | |
Management Performance
| Return On Equity | 0.31 | ||||
| Return On Asset | 0.083 |
Genpact Limited Leadership Team
Elected by the shareholders, the Genpact's board of directors comprises two types of representatives: Genpact inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Genpact. The board's role is to monitor Genpact's management team and ensure that shareholders' interests are well served. Genpact's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Genpact's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Piyush Mehta, Chief Human Resources Officer, Senior Vice President | ||
| Edward Fitzpatrick, Chief Financial Officer, Senior Vice President | ||
| CFA CFA, VP CFO | ||
| Carol Lindstrom, Independent Director | ||
| Kathryn Stein, Senior Vice President, Chief Strategy Officer and Global Business Leader, Enterprise Services | ||
| Edward CPA, Senior Advisor | ||
| Nallicheri Tyagarajan, CEO President | ||
| Krista Bessinger, Head Relations | ||
| Jim Madden, Independent Director | ||
| Brian Stevens, Independent Director | ||
| CeCe Morken, Director | ||
| Kevin Webb, Head Services | ||
| Michael CFA, Senior CFO | ||
| Laura Conigliaro, Independent Director | ||
| Tamara Franklin, Independent Director | ||
| Ezra Baylin, Head Acquisitions | ||
| Hailey Eichner, Chief CEO | ||
| Victor Guaglianone, Senior Vice President General Counsel, Corporate Secretary | ||
| CeCelia Morken, Independent Director | ||
| Mark Verdi, Independent Director | ||
| Vipin Gairola, Global Officer | ||
| Hanspeter Spek, Independent Director | ||
| Darren Saumur, Senior Vice President Global Operating Officer | ||
| Sameer Dewan, Senior Leader | ||
| Patrick Cogny, Senior Vice President - Infrastructure, Manufacturing & Services and High Tech | ||
| Robert Scott, Independent Non-Executive Chairman of the Board | ||
| Mohit Thukral, Sr. VP of Banking, Financial Services and Insurance | ||
| Ahmed Mazhari, Senior Vice President Chief Growth Officer | ||
| Ajay Agrawal, Independent Director | ||
| Michael Weiner, Chief Financial Officer, Senior Vice President | ||
| Roger CFA, Head Relations | ||
| Alex Mandl, Independent Director | ||
| Balkrishan Kalra, Senior Vice President - Banking, Capital Markets, Consumer Goods, Retail, Life Sciences and Healthcare | ||
| Heather White, Senior Vice President, Chief Legal Officer, Corporate Secretary | ||
| Vidya Rao, Chief Officer | ||
| N Tyagarajan, President, Chief Executive Officer, Director | ||
| Anil Nanduru, Consumer Manufacturing | ||
| Stacey Cartwright, Independent Director | ||
| Donald Klunk, Chief Officer | ||
| Mohit Bhatia, Sr. VP and Internal Transformation Leader | ||
| Rajiv Naidu, Business Affairs | ||
| Mark Nunnelly, Independent Director | ||
| James Madden, Non-Executive Independent Chairman of the Board | ||
| Caitlin Blewett, Chief Officer | ||
| Riju Vashisht, Chief Officer | ||
| Arvinder Singh, Sr. VP and Bus. Leader of Capital Markets and IT Services | ||
| Amit Chandra, Independent Director | ||
| David Humphrey, Independent Director |
Genpact Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Genpact a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.31 | ||||
| Return On Asset | 0.083 | ||||
| Profit Margin | 0.14 % | ||||
| Operating Margin | 0.14 % | ||||
| Current Valuation | 6.62 B | ||||
| Shares Outstanding | 180.33 M | ||||
| Shares Owned By Insiders | 1.00 % | ||||
| Shares Owned By Institutions | 99.00 % | ||||
| Number Of Shares Shorted | 4.42 M | ||||
| Price To Earning | 28.59 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genpact Limited. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the Genpact Limited information on this page should be used as a complementary analysis to other Genpact's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Complementary Tools for Genpact Stock analysis
When running Genpact's price analysis, check to measure Genpact's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genpact is operating at the current time. Most of Genpact's value examination focuses on studying past and present price action to predict the probability of Genpact's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genpact's price. Additionally, you may evaluate how the addition of Genpact to your portfolios can decrease your overall portfolio volatility.
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |
Is Genpact's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Genpact. If investors know Genpact will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Genpact listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 2.311 | Dividend Share 0.55 | Earnings Share 3.41 | Revenue Per Share 24.552 | Quarterly Revenue Growth 0.04 |
The market value of Genpact Limited is measured differently than its book value, which is the value of Genpact that is recorded on the company's balance sheet. Investors also form their own opinion of Genpact's value that differs from its market value or its book value, called intrinsic value, which is Genpact's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Genpact's market value can be influenced by many factors that don't directly affect Genpact's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Genpact's value and its price as these two are different measures arrived at by different means. Investors typically determine if Genpact is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Genpact's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.